slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 69,511-69,540
Pages 3,679
Rows per page 30
Component
69,511-69,540 of 110,355
04
The slide uses a Gantt-style chart to represent clinical trial progress.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
06
The slide uses a human silhouette to map clinical manifestations to specific body systems.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Includes two testimonials from Key Opinion Leaders (KOLs) to emphasize the patient burden.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses a pie chart to show patient segmentation by B6 responsiveness and a timeline/number line to show age of diagnosis, followed by key metrics on clinical complications.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
Includes a biological process diagram showing intracellular vs plasma metabolism.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
11
The chart displays efficacy data for a drug candidate, noting the impact of anti-drug antibodies (ADAs) on the third cohort.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution1 hit
15
The slide uses a timeline-based visual to show disease progression.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
16
The slide uses a two-column layout to contrast commercial/regulatory status with clinical trial outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
17
The slide presents two distinct clinical metrics: a box plot for arginine levels and a bar chart for patient response rates.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
18
Clinical trial data presentation with statistical significance markers and MCID thresholds.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
20
Clinical trial safety data comparing Pegzilarginase to Placebo.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
22
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
24
The slide uses a biological pathway diagram to explain the mechanism of action of the drug candidate.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
25
Includes a Kaplan-Meier survival curve and a comparative table of clinical outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
26
The chart shows a clear dose-response relationship where the 10.0 mg/kg dose achieves a more significant and sustained reduction in tHcy compared to the 1.0 mg/kg dose.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
27
The slide uses two distinct chart types (Kaplan-Meier survival curve and a time-series pharmacodynamic plot) to support the clinical hypothesis.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
30
The table displays mean/SD and median/range for Plasma Arginine, GMFM-E, and 2MWT, and counts/percentages for GMFCS levels.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
31
Box plot visualization of clinical trial results.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
32
Includes both continuous mean change data and categorical responder analysis.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
33
Includes a study design timeline and MCID reference lines for GMFCS levels.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
34
The slide outlines standard clinical outcome assessments (COAs) for motor function.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
01
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Attention1 hit
06
Includes a highlighted column for Q1'23 and detailed footnotes regarding product licensing and arbitration.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
09
The chart illustrates the revenue contribution of four products: VIVITROL, ARISTADA, VUMERITY, and LYBALVI.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
10
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
11
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
12
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
15
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
17
The slide outlines a two-stage clinical development strategy with specific objectives and assessment criteria for each phase.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
03
The slide includes a footnote explaining F/X adjusted metrics.Amazon | Results Presentation Deck | 19 slides · Amazon
Conference presentation Investor relations Beat · Financials1 hit